Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Common Equity (2020 - 2025)

Universe Pharmaceuticals' Common Equity history spans 6 years, with the latest figure at $56.1 billion for Q3 2025.

  • On a quarterly basis, Common Equity rose 23.35% to $56.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $56.1 billion, a 23.35% increase, with the full-year FY2025 number at $56.1 billion, up 23.35% from a year prior.
  • Common Equity hit $56.1 billion in Q3 2025 for Universe Pharmaceuticals, up from $45.5 billion in the prior quarter.
  • Over the last five years, Common Equity for UPC hit a ceiling of $56.1 billion in Q3 2025 and a floor of $47.0 million in Q3 2021.
  • Historically, Common Equity has averaged $33.0 billion across 5 years, with a median of $35.3 billion in 2022.
  • Biggest five-year swings in Common Equity: surged 75083.64% in 2022 and later dropped 20.83% in 2023.
  • Tracing UPC's Common Equity over 5 years: stood at $47.0 million in 2021, then surged by 75083.64% to $35.3 billion in 2022, then fell by 20.83% to $28.0 billion in 2023, then soared by 62.68% to $45.5 billion in 2024, then rose by 23.35% to $56.1 billion in 2025.
  • Business Quant data shows Common Equity for UPC at $56.1 billion in Q3 2025, $45.5 billion in Q3 2024, and $28.0 billion in Q3 2023.